Abstract
Scientific Abstracts requiring hospitalization): 2% vs 0.2% and the risk presentation format: numbers only, numbers + IA, numbers + BB, and numbers + IA + BB. Route of administration, benefit, and cost were held constant. Each subject responded to a single, randomly-assigned scenario. Dependent variables included perceived riskiness, worry, global gist related to the acceptability of the AE, and willingness to take the medication (all measured on 5-point ordinal scales). We hypothesized that the IA and BB formats would result in 1) lower perceived riskiness and worry, and 2) greater acceptability of the AE and willingness to take the medication in the 0.2% vs 2% scenarios. Socioeconomic status (SES) was defined based on difficulty paying for medication and education level. Results: We mailed 1453 surveys. 465 patients completed and mailed the survey back (32% response rate). Overall, the mean age of responders was 58.99 (SD=14.85); 79.7% of were female; 83.2% White and 39.1% had a low SES. There were no statistical differences in demographic or clinical characteristics across the four risk presentation formats. Mean (SD) perceived riskiness, worry, global gist, and willingness to take the medication for 2% versus 0.2% chance of the AE, by SES level, are presented in the Image. Perceived riskiness was lower for a 0.2% versus 2% risk of the AE in the numbers + IA condition in higher SES subjects. Lower SES subjects who viewed both IA and BB were more worried about the AE and found the AE to be less acceptable in the 0.2% versus 2% condition.
Abstract
With the exception of the IA's impact on perceived riskiness among subjects with higher SES, the risk formats used did not enable subjects to correctly differentiate between a 0.2% and a 2% risk of a serious AE. These results highlight the lack of impact of quantitative risk information on patients' risk perceptions.
Thursday, 15 June 2017
Scientific Abstracts requiring hospitalization): 2% vs 0.2% and the risk presentation format: numbers only, numbers + IA, numbers + BB, and numbers + IA + BB. Route of administration, benefit, and cost were held constant. Each subject responded to a single, randomly-assigned scenario. Dependent variables included perceived riskiness, worry, global gist related to the acceptability of the AE, and willingness to take the medication (all measured on 5-point ordinal scales). We hypothesized that the IA and BB formats would result in 1) lower perceived riskiness and worry, and 2) greater acceptability of the AE and willingness to take the medication in the 0.2% vs 2% scenarios. Socioeconomic status (SES) was defined based on difficulty paying for medication and education level.
Results:
We mailed 1453 surveys. 465 patients completed and mailed the survey back (32% response rate). Overall, the mean age of responders was 58.99 (SD=14.85); 79.7% of were female; 83.2% White and 39.1% had a low SES. There were no statistical differences in demographic or clinical characteristics across the four risk presentation formats. Mean (SD) perceived riskiness, worry, global gist, and willingness to take the medication for 2% versus 0.2% chance of the AE, by SES level, are presented in the Image. Perceived riskiness was lower for a 0.2% versus 2% risk of the AE in the numbers + IA condition in higher SES subjects. Lower SES subjects who viewed both IA and BB were more worried about the AE and found the AE to be less acceptable in the 0.2% versus 2% condition.
Conclusions:
With the exception of the IA's impact on perceived riskiness among subjects with higher SES, the risk formats used did not enable subjects to correctly differentiate between a 0.2% and a 2% risk of a serious AE. 2016) in Germany and on the price differential between etanercept biosimilar and the reference product, a total cost saving of 8.8 million EUR was realized during the analysis period. Assuming these patients remain on etanercept biosimilar treatment, a total savings of 21.1 million EUR** can be returned annually to the healthcare system, compared to using only the reference product. This annual cost savings could be utilized to provide treatment to additional 1,208 patients with etanercept biosimilar. 

{'paper_id': '80607703', 'title': 'THU0656 Etanercept biosimilar usage and associated cost savings in germany', 's2_url': 'https://api.semanticscholar.org/CorpusID:80607703', 'source': 'S2ORC'}